Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 6:14 PM ET

Healthcare Equipment and Supplies

Company Overview of Saladax Biomedical, Inc.

Company Overview

Saladax Biomedical, Inc. develops and commercializes diagnostic blood tests for the practical delivery of personalized medicine in oncology. It offers MyCare chemotherapy exposure optimization tests, such as My5-FU, a chemotherapy used in the treatment of colorectal, breast, and head and neck cancers; MyPaclitaxel, a chemotherapy used in the treatment of breast, non-small cell lung, ovarian, and digestive tract cancers; and MyDocetaxel, a chemotherapy used in the treatment of breast cancer, as well as non-small cell lung, digestive tract, prostate, and head and neck cancers. The company also provides MyImatinib, which measures and helps physicians optimize a patient's exposure to imatinib (g...

116 Research Drive

Bethlehem, PA 18015

United States

Founded in 2004





Key Executives for Saladax Biomedical, Inc.

Founder, President and Director
Founder and Director
Vice President of R&D and Operations
Director of Worldwide Marketing
Compensation as of Fiscal Year 2015.

Saladax Biomedical, Inc. Key Developments

Saladax Biomedical, Inc. Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test

Saladax Biomedical, Inc. announced the commercial launch of the MyImatinib(TM) test. MyImatinib is part of the Saladax line of MyCare(TM) diagnostic tests that determine a patient's exposure to chemotherapy in an effort to improve and personalize dosing. The MyCare tests are simple blood tests that provide oncologists with specific information about each patient's exposure to chemotherapy, helping the doctor to make informed decisions on drug dose adjustments, with the goals of maximizing the therapy's effectiveness and limiting its potential side effects. The MyImatinib tests will be managed through the Saladax Biomedical Laboratories (SBL), the CLIA-certified division of Saladax Biomedical. Imatinib is used in the treatment of multiple cancers, and is marketed in the United States by Novartis as Gleevec(R). MyImatinib joins the Saladax portfolio of tests that currently include My5-FU(TM), MyPaclitaxel(TM) and MyDocetaxel(TM). The MyCare tests are designed to provide oncologists with accurate, convenient and reliable information regarding Imatinib exposure levels.

Similar Private Companies By Industry

Company Name Region
SiTeS Medical, LLC United States
Bryton Corporation United States
Ncrx Optical Solutions Inc. United States
Femasys Inc. United States
Flower Orthopedics Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Saladax Biomedical, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at